title: Use of slow-release melatonin in treatment-resistant depression.
abstract: OBJECTIVE
  To examine antidepressant augmentation with and hypnotic effects of slow-release melatonin (SR-melatonin) in patients with treatment-resistant depression.
  
  
  METHODS
  Open-label trial.
  
  
  METHODS
  Tertiary care outpatient depression clinic.
  
  
  METHODS
  Nine outpatients who had failed to respond to 2 or more 8-week trials of antidepressant medication.
  
  
  METHODS
  Patients received SR-melatonin 5 mg per day for the first 2 weeks and 10 mg per day for the final 2 weeks, in addition to their antidepressant medication.
  
  
  METHODS
  Structured Clinical Interview for DSM-IV, Axis 1 Disorders, Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory, Response Style Questionnaire, sleep and fatigue measures.
  
  
  RESULTS
  One patient was excluded after 1 week because of the development of a mixed affective state. In the remaining 8 patients there was a 20% mean decrease in HRSD scores after 4 weeks of treatment, with no individual achieving an improvement of 50% or more. There was a 36% decrease on the 3-item HRSD related to insomnia, with 4 of 8 patients showing at least a 50% improvement on this measure. The greatest decrease in insomnia occurred during the last 2 weeks of the study, following the increase in dosage to 10 mg per day of SR-melatonin. Patients also reported significantly lower levels of fatigue post-treatment.
  
  
  CONCLUSIONS
  SR-melatonin may be a useful adjunct for sleep, but does not substantially augment existing antidepressant therapies in some patients with treatment-resistant depression.
authors.affiliation: Depression Clinic, Centre for Addiction and Mental Health (CAMH-Clarke), Toronto, Ont.
authors.forename: E J
authors.initials: EJ
authors.lastname: Dalton
authors.forename: D
authors.initials: D
authors.lastname: Rotondi
authors.forename: R D
authors.initials: RD
authors.lastname: Levitan
authors.forename: S H
authors.initials: SH
authors.lastname: Kennedy
authors.forename: G M
authors.initials: GM
authors.lastname: Brown
mesh_terms: D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008550:Melatonin / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D010555:Personality Inventory
chemical_list: D000928:Antidepressive Agents; D003692:Delayed-Action Preparations; D008550:Melatonin